Teva has received approval from the US Food and Drug Administration (FDA) to market a generic version of Plavix (Clopidogrel) developed by pharmaceutical company Sanofi. Total US sales of the drug, designed to prevent blood clotting, totaled $ 6.8 billion in the last 12 months, according to medical research agency IMS. In 2007, Plavix was the second-most prescribed drug in the world, after Lipitor (Atorvastatin).
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
Top Tel Aviv Hospital Using AI In Neurological Therapy
April 18, 2024
Israel Foodtech Firms Meet UK Retailers, Investors In London
April 17, 2024
Facebook comments